Many MedTech companies end up with the wrong cybersecurity vendor. Not because they don’t care about security, and not because good options don’t exist. They pick the wrong one because they don’t know what separates a firm that has lived inside FDA submissions from one that handles enterprise IT and is willing to give medical devices a try. Finding the best medical device cybersecurity company for your submission isn’t about searching for the biggest brand or the longest feature list. It’s about knowing exactly what the FDA expects and then verifying that your vendor has delivered it before, repeatedly, across real submissions.
Blue Goat Cyber was founded with an exclusive focus on medical device manufacturers and has supported FDA submissions across 510(k), De Novo, and PMA pathways. That kind of depth doesn’t come from reading guidance documents. It comes from repeated pattern recognition built across years of submission work. By the end of this guide, you’ll have a clear framework to evaluate any vendor, not just a list of names. Use it before you sign anything.
Why Most Cybersecurity Vendors Won’t Survive Your FDA Submission
Many general IT security firms are not well-equipped for FDA submission work. Being skilled at SOC 2 audits, enterprise zero-trust architecture, or endpoint detection has little to do with writing a threat model that FDA reviewers will accept. The standards are different. The documentation structure is different. And the stakes are higher than most general practitioners realize.
ISO 14971 governs risk management for medical devices. IEC 62304 governs software lifecycle processes. AAMI TIR57 addresses cybersecurity risk management specifically within the medical device context. None of these map neatly to the frameworks that enterprise cybersecurity firms spend their careers in. A vendor who doesn’t live in this regulatory environment will learn on your dime, and that education is expensive.
What Happens When a Generalist Handles Your FDA Submission
The consequence path is predictable: inadequate documentation, a deficiency letter, a resubmission, and months of delay. Cybersecurity deficiencies are a frequent cause of 510(k) submissions stalling. Common triggers include missing threat models, incomplete SBOMs, insufficient penetration testing evidence, and postmarket plans that don’t meet Section 524B obligations. A deficiency cycle can push your product significantly behind schedule and generate real costs in delayed revenue, rework, and extended consulting fees. A specialist avoids this pattern. A generalist creates it.
How to Choose the Best Medical Device Cybersecurity Company: Key Criteria
Here is the framework. Apply it to every vendor you evaluate, including the ones that come recommended. Vague credentials don’t hold up under direct questions.
Depth of FDA Submission Experience
Ask specifically how many premarket cybersecurity submissions the firm has supported in the last 24 months. “Experience with FDA” is not an answer. Supporting 510(k), De Novo, and PMA submissions requires knowing what reviewers accept and reject at the documentation level. Firms with genuine depth reference UL 2900-1 and AAMI TIR57 fluently because they use them constantly. Firms that don’t bring those standards up unprompted probably haven’t worked inside enough submissions to know where they matter.
Full-Lifecycle Capability Versus Point-in-Time Services
Vendors who only offer penetration testing, or only review documentation, create gaps. A complete premarket submission requires design consulting, secure product development framework (SPDF) documentation, SBOM creation, threat modeling, penetration testing, eSTAR documentation, and postmarket planning. Ask any vendor you’re considering whether they can stay with you after clearance. Section 524B requires ongoing monitoring, patch management, and vulnerability disclosure processes for cleared devices. A vendor who disappears after submission leaves you exposed on the postmarket side.
For guidance on selecting the right firm for FDA-focused work, see How to Choose a Cybersecurity Firm for FDA Submissions, Blue Goat Cyber.
Standards Coverage Breadth
ISO 14971, IEC 62304, IEC 62443-4-1, and UL 2900 are not optional references. They are the scaffolding of a defensible FDA submission. A vendor who covers only one or two of these creates compliance gaps that will surface during FDA review or notified body audits. Before you engage anyone, ask them to walk you through how each standard applies to your device class. The answer tells you exactly how deep their knowledge runs.
Turnaround Time with Documented Quality
Speed matters in MedTech, but not at the expense of quality. Ask for documented delivery timelines and find out how many active engagements the firm runs simultaneously. A small team taking on too many clients will stretch timelines without telling you until it’s a problem. The right partner delivers thorough, FDA-ready reports on schedule because they have the team depth to execute, not just the sales pitch to win the deal.
Deficiency Response Track Record
Any vendor worth hiring should be able to show they’ve resolved FDA cybersecurity deficiency letters, not just helped clients avoid them. Deficiency resolution is the truest test of submission fluency because it requires understanding exactly what a reviewer objected to and rebuilding documentation to clear the objection. Ask for a specific example. If they can’t give you one, you should know what that means.
What FDA Cybersecurity Submissions Actually Require from a Partner
The FDA’s 2026 final guidance, “Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions,” is not ambiguous about what a premarket submission must contain.
Premarket Documentation: What Must Be Included
A defensible submission includes several required elements. At the documentation level, that means a system-level threat model using a framework like STRIDE, a cybersecurity risk assessment tied to ISO 14971, and a Software Bill of Materials (SBOM) in machine-readable format such as SPDX or CycloneDX. It also requires secure product development framework (SPDF) and SDLC descriptions, penetration testing evidence, and security architecture documentation. Labeling language covering ports and update procedures and a cybersecurity management plan addressing postmarket obligations round out the package. Missing or thin documentation in any of these areas is what triggers a deficiency letter.
eSTAR-Ready Deliverables
The FDA’s eSTAR template has been mandatory for 510(k) submissions since October 1, 2023. It includes a dedicated cybersecurity section with specific fields for threat models, SBOMs, testing evidence, and postmarket plans. Automated checks flag incomplete sections before submission, meaning gaps are caught by the system before a human reviewer ever sees the file. A vendor who doesn’t structure deliverables directly into the eSTAR format from day one adds revision cycles you don’t need. The FDA’s own resources on device cybersecurity can help clarify eSTAR expectations: FDA FAQs on Cybersecurity for Medical Devices.
Postmarket Obligations Your Vendor Should Prepare You For
Under Section 524B of the FD&C Act, cleared devices require ongoing cybersecurity monitoring, patch management, coordinated vulnerability disclosure processes, and documented metrics like time-to-patch. Vendors who serve only the premarket side leave manufacturers without a compliance structure for the operational life of the device. This is not a secondary concern. It’s a statutory requirement.
What a Best-in-Class Medical Device Cybersecurity Firm Looks Like in Practice
Run the criteria from the previous section against Blue Goat Cyber and the alignment is clear. The evaluation framework points in one direction when you apply it to a firm built exclusively around this problem.
Exclusive Specialization as a Structural Advantage
Blue Goat Cyber works exclusively with medical device manufacturers and MedTech companies. There are no enterprise IT clients competing for the same team’s attention, no generalist consulting engagements running alongside FDA submission work. That focus matters because FDA cybersecurity guidance evolves, and a firm tracking only this regulatory category catches guidance updates, eSTAR changes, and reviewer expectation shifts faster than any generalist monitoring dozens of sectors at once.
Track Record Across FDA Submissions
Since 2014, Blue Goat Cyber has supported a substantial volume of 510(k) and De Novo submissions. That depth of experience produces pattern recognition that newer entrants and generalist firms cannot replicate. When a reviewer objects to a specific documentation structure, the team has encountered that objection before and knows how to resolve it. Deficiency response capability is a direct product of submission experience, not a service add-on.
The “Done for You” Delivery Model
Regulatory affairs managers are already managing cross-functional teams, product timelines, and internal compliance processes. Offloading the entire cybersecurity workload to a specialized firm isn’t a luxury. It’s a risk management decision. Blue Goat Cyber handles SPDF documentation, SBOM creation, threat modeling, penetration testing, and eSTAR documentation end-to-end, so device teams can focus on the product itself rather than learning a compliance framework under deadline pressure.
For founders who are early in planning and need a roadmap from concept through clearance, read From Idea to FDA Clearance: What Nobody Tells MedTech Founders, Blue Goat Cyber.
Questions to Ask the Best Medical Device Cybersecurity Company Before You Sign
These questions are designed to surface vendors who are genuinely qualified versus ones who will figure it out at your expense. Use them in every vendor call.
Questions That Test FDA Submission Fluency
Ask how many premarket submissions the firm has supported in the last 24 months. Ask them to describe a cybersecurity deficiency letter they’ve resolved and what the resolution required. Ask whether their deliverables are structured for the FDA’s eSTAR template from day one or adapted afterward. A vendor who hedges on any of these questions, or pivots to general cybersecurity credentials instead of specific FDA submission experience, deserves careful scrutiny before you proceed.
Questions That Reveal Delivery Depth
Ask whether they handle SBOM creation or require your team to provide it. Ask what their postmarket monitoring offering includes after clearance. Ask for a documented turnaround timeline from engagement start to FDA-ready deliverables. These questions separate full-service partners from boutique firms that do one or two things well and leave the rest as your problem. The answers should be specific and immediately available. If a vendor needs time to check internally, that tells you something about how often they actually do this work.
How to Build Your Shortlist and Make the Final Call
The right vendor depends on your stage, your device type, and your internal capacity. Before building a shortlist, identify which category of vendor your challenge actually requires.
Matching Vendor Type to Your Actual Need
IoMT visibility platform vendors like Claroty, Asimily, and Armis are purpose-built for healthcare networks managing deployed devices at scale. They focus on agentless discovery, real-time anomaly detection, and continuous vulnerability monitoring across live hospital environments. If your challenge is securing connected devices already deployed in clinical networks, these platforms address that specific need. See vendor guidance such as How to Choose the Right IoMT Security Vendor when evaluating network-focused solutions, and consider discovery/inventory offerings like healthcare discovery and inventory if you need agentless device visibility. If your challenge is getting a device through FDA clearance or responding to a deficiency letter, you need a premarket cybersecurity consulting firm with FDA submission depth. These are different categories. Selecting the wrong type is a common and costly mistake.
Making the Call with Confidence
Apply the five criteria from this guide, run each candidate through the screening questions, and prioritize firms with exclusive medical device focus and verifiable FDA submission history. Finding the best medical device cybersecurity company comes down to one filter: specialization. Broad credentials don’t clear deficiency letters. FDA submission experience does. For MedTech founders and regulatory affairs managers navigating a 510(k) or De Novo, Blue Goat Cyber is built specifically for this work. Reach the team directly at bluegoatcyber.com to discuss your device, your timeline, and what a full-service engagement looks like for your specific submission.
Choosing the best medical device cybersecurity company isn’t complicated once you know what to filter for. Specialization outperforms breadth. FDA submission experience outperforms general cybersecurity credentials. A full-service delivery model outperforms fragmented point solutions that leave documentation gaps. Apply this framework honestly, and the right partner becomes clear. Don’t let the wrong vendor slow down a product that patients are waiting for.
For additional context on industry trends and vendor comparisons, you may also find third-party market research and vendor lists helpful when building your long and short lists.
Related: The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks